Cladribine tablets in high disease activity (HDA) subgroups from the CLARITY study of patients with relapsing multiple sclerosis (RMS)

Category Primary study
ConferenceEuropean Journal of Neurology
Year 2017
This article has no abstract
Epistemonikos ID: 4f9f69cd02ffcff40a937ad0f7c902fe637b7a86
First added on: Apr 29, 2026